Effect of Empagliflozin in Preventing Progression of Renal Dysfunction in Diabetic Patients With Compensated Heart Failure
Open Access
- 10 June 2021
- journal article
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 3 (6), 358
- https://doi.org/10.1253/circrep.cr-20-0142
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Empagliflozin Administration Can Decrease the Dose of Loop Diuretics and Prevent the Exacerbation of Renal Tubular Injury in Patients With Compensated Heart Failure Complicated by DiabetesCirculation Reports, 2020
- Dapagliflozin in Patients with Chronic Kidney DiseaseThe New England Journal of Medicine, 2020
- Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trialEuropean Journal of Heart Failure, 2019
- Update of acute and long-term tolvaptan therapyJournal of Cardiology, 2018
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesThe New England Journal of Medicine, 2016